De­ci­pher­a's GIST ther­a­py ripretinib wins speedy FDA re­view — set­ting the stage for bat­tle with ri­val Blue­print

Blue­print Med­i­cines has the edge on tim­ing with its ri­val can­cer drug Ay­vak­it, but De­ci­phera Phar­ma­ceu­ti­cals is not far be­hind. On Wednes­day, the Waltham, Mass­a­chu­setts-based com­pa­ny dis­closed it had se­cured a speedy re­view for its drug ripretinib and an Au­gust de­ci­sion date.

Both pre­ci­sion ther­a­pies are de­signed to treat gas­troin­testi­nal stro­mal tu­mors (GIST) — a rare form of sar­co­ma found in the di­ges­tive sys­tem, most of­ten in the wall of the stom­ach.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER